Bispecifics in R/R MM: AE Management and Sequencing

Panelist discusses how every drug oncologists use comes with adverse events (AEs), and with bispecifics they are seeing a similar AE profile to that seen in CAR T-cell therapy. There are 3 major AEs: cytokine release syndrome, neurological toxicity, and infections. To manage AEs, oncologists are now monitoring patients more intensely as well as engaging with the patient’s family to provide updates on the status of the patient.